Company profile
Allotera Therapeutics
A new era of Allogeneic T-Cell Therapies
- Industry
- Biotechnology Research
- Employees
- 45
- Headquarters
- St. Louis, Missouri
- Founded
- 2018
- LinkedIn followers
- 5,953
- Office locations
- 1
Allotera Therapeutics company summary
Allotera Therapeutics is a company in the Biotechnology Research industry, headquartered in St. Louis, Missouri, founded in 2018. On LinkedIn the company has around 45 employees and 5,953 followers.
What technology does Allotera Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Allotera Therapeutics
Allotera Therapeutics, Inc., headquartered in St. Louis, Missouri, is a clinical-stage biotechnology company focused on developing next-generation, allogeneic CAR-T cell therapies for cancer. Allotera’s proprietary gene-editing platform is designed to overcome key limitations of first-generation cell therapies, enabling scalable, off-the-shelf treatments with biologics-like cost of goods margins. The lead program, WU‑CART-007, targets CD7 and has demonstrated best-in-class efficacy in T-ALL/T-LBL, with the potential to be the first approved allogeneic CAR-T therapy for T-cell malignancies.
Where is Allotera Therapeutics located?
Allotera Therapeutics lists 1 location.
Compare companies similar to Allotera Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Allotera Therapeutics alloteratx.com | Biotechnology Research | 45 | 2018 | St. Louis, Missouri |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Allotera Therapeutics
What does Allotera Therapeutics do?
Allotera Therapeutics, Inc., headquartered in St. Louis, Missouri, is a clinical-stage biotechnology company focused on developing next-generation, allogeneic CAR-T cell therapies for cancer. Allotera’s proprietary gene-editing platform is designed to overcome key limitations of first-generation cell therapies, enabling scalable, off-the-shelf treatments with biologics-like cost of goods margins. The lead program, WU‑CART-007, targets CD7 and has demonstrated best-in-class efficacy in T-ALL/T-LBL, with the potential to be the first approved allogeneic CAR-T therapy for T-cell malignancies.
How many employees does Allotera Therapeutics have?
Allotera Therapeutics has around 45 employees on LinkedIn.
Where is Allotera Therapeutics headquartered?
Allotera Therapeutics is headquartered in St. Louis, Missouri.
When was Allotera Therapeutics founded?
Allotera Therapeutics was founded in 2018.
Build a lead list from companies like Allotera Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.